β-Site APP-cleaving enzyme 1 (BACE1) inhibition is considered one of the most promising therapeutic strategies for Alzheimer's disease, but current BACE1 inhibitors also block BACE2. As the localization and function of BACE2 in the brain remain unknown, it is difficult to predict whether relevant side effects can be caused by off-target inhibition of BACE2 and whether it is important to generate BACE1-specific inhibitors. Here, we show that BACE2 is expressed in discrete subsets of neurons and glia throughout the adult mouse brain. We uncover four new substrates processed by BACE2 in cultured glia: vascular cell adhesion molecule 1, delta and notch-like epidermal growth factor-related receptor, fibroblast growth factor receptor 1, and plexi...
SummaryBACE1 is the major drug target for Alzheimer's disease, but we know surprisingly little about...
The β-site APP cleaving enzymes 1 and 2 (BACE1 and BACE2) were initially identified as transmembrane...
Inhibition of Beta-site- APP Cleaving Enzyme-1 (BACE-1) is a current approach to fight the β-amyloid...
β-Site APP-cleaving enzyme 1 (BACE1) inhibition is considered one of the most promising therapeutic ...
Alzheimer’s disease (AD) is the most common form of dementia clinically characterized by a significa...
β-Secretase, the rate-limiting enzymatic activity in the production of the amyloid-β (Aβ) peptide, i...
Alzheimer’s disease (AD) is the most common form of dementia clinically characterized by a significa...
Inhibition of the protease β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) is a promising...
Abstractβ-site APP cleaving enzyme 1 (BACE1) is the β-secretase enzyme required for generating patho...
BACE1 is a key enzyme for amyloid-β (Aβ) production, and an attractive therapeutic target in Alzheim...
The β‐site amyloid precursor protein cleaving enzyme‐1 (BACE1), an essential protease for the genera...
peer reviewedBeta-secretase (BACE1) is the rate-limiting protease for the generation of the amyloid ...
International audienceBACE1 (beta-site amyloid precursor protein cleaving enzyme 1) was initially cl...
BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) was initially cloned and characterized...
BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) was initially cloned and characterized...
SummaryBACE1 is the major drug target for Alzheimer's disease, but we know surprisingly little about...
The β-site APP cleaving enzymes 1 and 2 (BACE1 and BACE2) were initially identified as transmembrane...
Inhibition of Beta-site- APP Cleaving Enzyme-1 (BACE-1) is a current approach to fight the β-amyloid...
β-Site APP-cleaving enzyme 1 (BACE1) inhibition is considered one of the most promising therapeutic ...
Alzheimer’s disease (AD) is the most common form of dementia clinically characterized by a significa...
β-Secretase, the rate-limiting enzymatic activity in the production of the amyloid-β (Aβ) peptide, i...
Alzheimer’s disease (AD) is the most common form of dementia clinically characterized by a significa...
Inhibition of the protease β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) is a promising...
Abstractβ-site APP cleaving enzyme 1 (BACE1) is the β-secretase enzyme required for generating patho...
BACE1 is a key enzyme for amyloid-β (Aβ) production, and an attractive therapeutic target in Alzheim...
The β‐site amyloid precursor protein cleaving enzyme‐1 (BACE1), an essential protease for the genera...
peer reviewedBeta-secretase (BACE1) is the rate-limiting protease for the generation of the amyloid ...
International audienceBACE1 (beta-site amyloid precursor protein cleaving enzyme 1) was initially cl...
BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) was initially cloned and characterized...
BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) was initially cloned and characterized...
SummaryBACE1 is the major drug target for Alzheimer's disease, but we know surprisingly little about...
The β-site APP cleaving enzymes 1 and 2 (BACE1 and BACE2) were initially identified as transmembrane...
Inhibition of Beta-site- APP Cleaving Enzyme-1 (BACE-1) is a current approach to fight the β-amyloid...